San Antonio Breast Cancer Symposium 2009: Highlights in Radiation Oncology. Outline
|
|
- Clinton Reeves
- 5 years ago
- Views:
Transcription
1 San Antonio Breast Cancer Symposium 2009: Highlights in Radiation Oncology Catherine Park, M.D. UCSF Radiation Oncology Outline IMRT Trial: Abstract#: 71 APBI for DCIS and IBC Background: ECOG 5194 Abstracts #: 951, 952 Background: ASTRO Consensus Statement Abstract #: 955 BRCA-1/BRCA-2: Abstract #: 959 Molecular phenotype and response to Neoadjuvant: Abstracts #: 957 Intraoperative Radiotherapy for BOOST treatment: Abstract #:
2 Abs #71: A Randomised Controlled Trial of Forward- Planned Intensity Modulated Radiotherapy (IMRT) for Early Breast Cancer: Interim Results at 2 Years Follow- Up. Coles CE, Barne- GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Hoole AF, Burnet NG, Wishart GS Cambridge Breast IMRT Trial : Methods Purpose: Single centre trial to investigate whether correction of dose inhomogeneities using IMRT reduces late toxicity and improves quality of life in pts with early breast cancer Methods: 1145 pts assessed for dose inhomogeneity in standard tangential plans as defined by the ICRU recommendations Pts with inhomogenous dose plans were randomized to either IMRT vs. Standard radiotherpay Pts with acceptable homogenous plans were treated with standard radiotherapy and followed 2
3 Cambridge Breast IMRT Trial : Methods Primary endpoint: photographic assessment of breast shrinkage Secondary endpoint: Photographic assessment of final cosmesis Clinical assessment of toxicity Patient-reported symptoms and quality of life Cambridge Breast IMRT Trial SCHEMA <2cm 3 of breast >107% N=330 Treated per standard T1-3, N0-1, M0; or Tis N=1145 3D imaging Dosimetry with standard tangen@al plans >2cm 3 of breast >107% N=813 RANDOMIZED STANDARD: CT- planned STANDARD: CT- planned Forward IMRT UK= 40Gy/15 FX 3
4 Cambridge Breast IMRT Trial: Interim Analysis Accrual: 6/03-6/07, completed 0.8% LR, 7 CBC, 16 DM, 12 deaths 3 of breast cancer Data from 632 randomized pts with 2 yr F/U No difference in Standard vs. IMRT for primary endpoint (shrinkage) Non- randomized had smaller breasts (p<0.0005) Improvement in telangiectasias in control vs. IMRT HR 1.63 ( ) In randomized pts with good surgical cosmesis, there was a significant improvement in final cosmesis with IMRT (p<0.038) No differences in Boost, Tam, Chemotherapy Outline IMRT Trial: Abstract#: 71 APBI for DCIS and IBC Background: ECOG 5194 Abstracts #: 951, 952 Background: ASTRO Consensus Statement Abstract #: 955 BRCA-1/BRCA-2: Abstract #: 959 Molecular phenotype and response to Neoadjuvant: Abstracts #: 957 Intraoperative Radiotherapy for BOOST treatment: Abstract #:
5 ECOG 5194: Local Excision Alone Without for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Coopera@ve Oncology Group Lorie L. Hughes, Molin Wang, David L. Page, Robert Gray, Lawrence J. Solin, Nancy E. Davidson, Mary Ann Lowen, James N. Ingle, Abram Recht, and William C. Wood ECOG 5194: Eligibility 5
6 ECOG 5194: Eligibility -Non-palpable disease -3 mm or larger -Suitable for lumpectomy, s/p excision with margin width >3mm Low or intermediate histologic grade: nuclear grade 1 or 2, limited or no foci of necrosis <2.5 cm High histologic grade: nuclear grade 3 atypia and comedo-type necrosis that was zonal (contiguous ductal spaces) <1.0 cm -Post-op MG required for any calcs; if + residual calcs disqualified -Receptor status not routinely determined -Central pathology in 97% of cases ECOG 5194: Results 6
7 ECOG 5194: Results Abs #951: Low Risk Ductal Carcinoma in situ (DCIS) Treated with Breast Conserving Surgery & Accelerated Partial Breast Irradation (APBI): Comparison of the Mammosite Registry Trial with Intergroup Study E5194 Sharad Goyal1, Frank Vicini2, Peter D. Beitsch3, Martin Keisch4, Jacqueline S. Jeruss5, Maureen Lyden6, Bruce G. Haffty1 7
8 Abs #901: METHODS A total of 194 patients with DCIS were treated between 2002 and 2004 on the Mammosite registry trial; of these, 70 patients met the enrollment criteria for E5194: 1. LIG: low to intermediate grade with a pathological size > 0.3cm but < 2.5cm and margins >3mm (n=40) or 2. HG: high grade, pathological size <1cm and margins >3mm (n=30). Abs #901: METHODS All patients were treated with lumpectomy followed by adjuvant APBI (34 Gy in 3.4 Gy fractions). Median follow-up for surviving patients was 51.5 months (range, ). Hormonal therapy was given to 51% of these patients (compared to 30% of patients on E5194). Statistical analysis used SAS (v 8.2). 8
9 Abs #951: RESULTS All cases LIG Cohort HG Cohort Number of Breasts (All breasts) N=70 N(%) 5- yr Actuarial Rate N=41 N(%) 5- yr Actuarial Rate N=29 5- yr Actuarial Rate Breast Only Failures (IBTR) 1 (1.4) 1.98% 0 (0.0) 0% 1 (3.4) 5.16% TR/MM Failures 1 (1.4) 1.98% 0 (0.0) 0% 1 (3.4) 5.16% E Failures 0 (0.0) 0% 0 (0.0) 0% 0 (0.0) 0% Contralateral Failure 1 (1.4) 2.04% 0 (0.0) 0% 1 (3.4) 5.56% Distant Failure 0 (0.0) 0% 0 (0.0) 0% 0 (0.0) 0% Disease- Free Survival % % % Overall Survival % % % Cause- specific Survival % % % Followup Time (Mo) Median Range , , ,81.0 Abs #951: RESULTS E 5194 cases Current LIG HIG LIG HIG Median Tumor Size 0.8 cm 0.6 cm 5 year IBTR 6.1% 15.3% 0% 5.3% 5 year CBC rate 3.5% 4.2% 0% 5.6% 5 year DFS 92.4% 5 year OS 96.5% 9
10 Abs #951: AUTHOR s CONCLUSIONS Adjuvant accelerated partial breast irradiation using Mammosite is a relatively convenient form of radiotherapy which shortens treatment time to 1 week. This study found that patients who met the criteria of E5194 treated with APBI had extremely low rates of recurrence: 0% vs. 6.1% in the low to intermediate grade (LIG) cohort and 5.3%vs. 15.3%in the high grade (HG) cohort. We conclude that all patients with DCIS who were eligible for E5194 have appreciable benefit in reducing the rate of IBTR using APBI. Abs #952: 3-Year Follow-up of the Partial Breast Irradiation Trial for DCIS using the MammoSite Brachytherapy Balloon Catheter Oscar E Streeter, Jr, MD1, Pamela Benitez, MD2, Frank Vicini, MD2, Vivek Mehta, MD3, Coral Quiet, MD4, Robert Kuske, MD4, Mary Hayes, MD5, Douglas Arthur, MD6, Henry Kuerer, MD7, Eric Strom, MD7, Gary Freedman, MD8, Mar@n Keisch, MD9, Thomas DiPetrillo, M.D10, David Khan, M.D11, Richard Hudes, MD12, Susan Groshen, PhD13, and Melvin J. Silverstein, M.D14 10
11 Abs #952: METHODS 100 patients entered from May 2003 through January 2006 The Mammosite balloon catheter was placed either at the time of lumpectomy or after the lumpectomy procedure with source optimization to provide the best conformance to the lumpectomy cavity. The minimum distance from the balloon surface to the skin surface (skin bridge distance) was > 5 mm. 34 Gy was delivered in 10 fractions over 5 days, each fraction was separated by at least 6 hours, and was prescribed to 1 cm from the applicator surface using an Iridium-192 high-dose rate brachytherapy applicator wire. The figure below demonstrates how the Mammosite Radiation Treatment System (MRTS) was delivered: Abs #952: METHODS > 45 years of age unicentric pure DCIS clinically node negative mammographic lesion of 3 cm or less lumpectomy negative margin (defined as 1 mm or more) postoperative final gross pathologic size of the removed tumor measuring 5 cm or less in its greatest dimension, post excision mammogram showing the absence of any residual suspicious micro-calcifications. Each patient was given a USC/Van Nuys Prognostic Index (USC/VNPI) score=6. If any of the eligibility criteria were not met and the MRTS was placed at the time of lumpectomy, it was explanted and the reason for removal was documented. 11
12 Abs #952: METHODS 133 patients were enrolled. mean age was 60.8 years. mean tumor size was 10.6 mm; mean actual closest margin was 6.8mm (range=0.1-40mm). balloon was placed post lumpectomy in 72% with a mean skin bridge of 13 mm, 89% of which were 7mm. median follow-up is 3 years. Harvard cosmetic results have been rated as excellent or good in 94% and fair in 6% with a follow-up time of at least 3 months in all of the patients treated. 84%were postmenopausal, 11% premenopausal, and 5% perimenopausal. ER+ 69% positive, 17% ER- and unknown in 14%. Fifty-two of the 100 women received endocrine therapy Abs #952: RESULTS There have only been four ipsilateral recurrences, all non-invasive; one was an ipsilateral recurrence outside the region of the original tumor cavity; There were no serious adverse events with an infection rate of only 9%-- 7 patients had breast infections, and 2 had cellulitis. 12
13 Abs #952: DISCUSSION This is the only prospective trial using the MammoSite or any other partial breast irradiation therapy technique for DCIS. It is well tolerated with an excellent to good cosmetic rate in 94% of the patients and fair in 6% of the patients with a 9% infection rate (7 breast infections; 2 cellulitis). There have been four recurrences, all noninvasive at this point. Each recurrence had at least one or more risk factors of a high USC/VNPI score, high nuclear grade, or comedo necrosis. There have not been any recurrences in nuclear grade 1 or nuclear grade 2 patients without comedo necrosis.. Accelerated Partial Breast Irradiation Consensus Statement from the American Society for Radiation Oncology (ASTRO) Benjamin D Smith, MD, DouglasW Arthur, MD, Thomas A Buchholz, MD, Bruce G Haffty, MD, Carol A Hahn, MD, Patricia H Hardenbergh, MD, Thomas B Julian, MD, Lawrence B Marks, MD, Dorin A Todor, PhD, Frank A Vicini, MD, Timothy J Whelan, MD, Julia White, MD, Jennifer YWo, MD, Jay R Harris, MD 13
14 APBI Patient Selection Criteria APBI Patient Selection Criteria 14
15 Abs #955: Outcomes following Accelerated Partial Breast Irradiation in ASTRO Consensus Statement Unsuitable Patients D.R. McHaffie, R.R. Patel, R.K. Das, H.M. Geye, G.M. Cannon at the University of Wisconsin. Abs #955: METHODS Between 2/2001 and 6/2006, a total of 322 consecutive patients were treated with HDR brachytherapy-based APBI All patients received Gy in 8 10 bid fractions using multicatheter (93.5%) or Mammosite balloon (6.5%) HDR brachytherapy. A total of 107 unsuitable patients were identified: 80 pts (74.7%) age < 50, 19 pts (17.8%) node positive, 20 pts (18.7%) with LVSI, 3 pts (2.8%) with tumors > 3 cm, and 2 pts (1.9%) with multifocal disease (Table 2). 17 pts (15.9%) had multiple unsuitable features and 53 pts (49.5%) possessed additional cautionary features. Estimates of IBTR, LRR, DFS, CSS, and OS were made using the Kaplan-Meier method. The log-rank test was used to assess differences between patient groups. 15
16 Abs #955: METHODS Abs #955: RESULTS The median follow-up is 60 months (range months). There were 6 in-breast tumor recurrences (IBTR), three of which had concurrent distant relapse. The 5 year actuarial rate of IBTR is 6.6% (95% CI: %). We observed 2 isolated axillary nodal failures. The 5 yr actuarial locoregional control rate is 91.3% (95% CI: %). The latency to LRR was months. Four of 5 patients without distant disease at the time of locoregional recurrence (LRR) were successfully salvaged and had no evidence of disease at last follow-up. 16
17 Abs #955: RESULTS 5 yr disease free survival for the entire cohort is 89%, with a cause-specific survival and overall survival of 92.5% and 89%, respectively. There were no loco-regional recurrences observed among those with age < 50 without other unsuitable (LVSI, node +, > 3 cm, multifocality) or cautionary (ER -, EIC, tumor 2 3 cm, lobular histology, DCIS, < 2 mm margins) features (n = 31). Abs #955: RESULTS In comparison, the loco-regional recurrence rate is 12.3% for those deemed unsuitable by virtue of surgical and pathologic factors or age <50 with tumor-related cautionary features (n = 76). No individual unsuitable feature was prognostic on unvariate analysis. Loco-regional recurrences were observed in 2/19 node positive pts, 3/20 pts with LVSI, 1/2 pts with multifocal disease, 2/34 with age < 50 alone and cautionary features, and 0/3 pts with tumors > 3 cm. 17
18 Abs #955: RESULTS # at risk Figure 1. Kaplan-Meier analysis of in-breast tumor recurrence (IBTR) probability. IBTR was defined as recurrence in the skin or parenchyma of the treated breast with or without concurrent regional or distant failure. No assessment of marginal miss versus elsewhere breast recurrences was made. Abs #955: RESULTS # at risk Figure 2. Kaplan-Meier analysis of loco-regional control probability. Eight loco-regional recurrences were observed, including 2 isolated nodal failures. 18
19 Abs #955: RESULTS Figure 3. Kaplan-Meier analysis of loco-regional control probability in women < 50 years who otherwise meet suitable criteria 0% (RED) versus women with adverse tumor-related features 12.3% (BLUE), p = Abs #955: AUTHOR s CONCLUSIONS The observed 5 yr loco-regional control rate of 91.3% +/- 5.7% is slightly lower than anticipated from historical breast conservation series, but confidence intervals are relatively large. Based upon the well-established benefits of whole breast radiotherapy, we continue to encourage clinical trial participation among this cohort of patients, specifically RTOG 0413 / NSABP B-39. Mature, phase III data are needed to guide patient selection. 19
20 Abs #955: AUTHOR s CONCLUSIONS Age < 50 years has consistently been shown to confer a higher risk of local recurrence following traditional breast conserving therapy. Although limited by patient numbers (n=31) and lack of statistical significance, the absence of local failures among women < 50 yrs without adverse histopathologic features (otherwise suitable) suggests they may be appropriate candidates for APBI. Outline IMRT Trial: Abstract#: 71 APBI for DCIS and IBC Background: ECOG 5194 Abstracts #: 951, 952 Background: ASTRO Consensus Statement Abstract #: 955 BRCA-1/BRCA-2: Abstract #: 959 Molecular phenotype and response to Neoadjuvant: Abstracts #: 957 Intraoperative Radiotherapy for BOOST treatment: Abstract #:
21 Abs #959: Local Therapy in BRCA1/2 Carriers with Operable Breast Cancer: Comparison of Breast Conservation and Mastectomy Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM Abs #959: METHODS Retrospective analysis of women prospectively followed with BRCA1/2 associated breast cancer Investigators from 10 institutions in the US, Spain, Israel and Australia identified women with invasive non-metastatic breast cancer and deleterious BRCA1/2 mutations treated with either BCT or Mx with or without PMRT. Statistical comparisons were made using the chi-square test for categorical characteristics and Student s t-test for continuous characteristics. 21
22 Abs #959: METHODS Rates of first failure and breast cancer-specific survival were estimated using the cumulative incidence method to account for competing events Cox regression models were constructed for local and distant failure, BCS OS and OS and CBC analyses Abs #959: RESULTS 655 patients with BRCA1/2 mutation and breast cancer were identified 302 were treated with BCT; 353 with Mx (241 without PMRT, 103 with PMRT and 9 RT unknown Median F/U: 8.2 years fo BCT and 8.9 years for Mx pts 22
23 Abs #959: RESULTS Abs #959: RESULTS 23
24 Abs #959: RESULTS Abs #959: AUTHOR s CONCLUSIONS We observed significantly greater local failures/new cancers following BCT vs. M in this cohort of BRCA1/2 carriers with early stage disease Use of chemotherapy significantly reduced the risk of local failures/new cancers following BCT Similar rates of distant failure, breast cancer-specific and overall survivals were observed between surgical cohorts. Comparable rates of systemic failure despite higher rates of IBTR suggest the development of new cancers in the treated intact breast rather than true IBTR s 24
25 Abs #959: AUTHOR s CONCLUSIONS Similar rates of CBC were observed independent of the use of RT suggesting no detectable increase in CBC attributable to scatter RT at 15 years These data may be helpful in discussions with patients with BRCA1/2 mutations and early stage cancer as they consider local treatment options. Outline IMRT Trial: Abstract#: 71 APBI for DCIS and IBC Background: ECOG 5194 Abstracts #: 951, 952 Background: ASTRO Consensus Statement Abstract #: 955 BRCA-1/BRCA-2: Abstract #: 959 Molecular phenotype and response to Neoadjuvant: Abstracts #: 957 Intraoperative Radiotherapy for BOOST treatment: Abstract #:
26 Abs #957: Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy TK Yu MD PhD, W Tereffe MD, I Bedrosian MD, S Eksambi, EA Strom MD, J Litton MD, AM Gonzalez-Angulo MD, TA Buchholz MD, KK Hunt MD, and EA Mittendorf MD Abs #957: METHODS Clinicopathologic data from 593 breast cancer patients who received NCT and BCT from 1997 to 2005 were reviewed. Gene profile subtypes by surrogate marker: Lum A (52%) = ER+ or PR+ and Her2- Lum B (9%)=ER+ or PR+ and Her2+ Her2+ (7%)= ER- and PR- and Her2+ Basal (32%) = ER- and PR- and Her2- All patients received NCT and adjuvant radiation (RT) 98% received Anthracycline-based chemotherapy 84% received Taxane None received Trastuzumab Actuarial rates were calculated using the Kaplan-Meier method and compared using long-rank test. Cox proportional hazards models were used for multivariate analysis 26
27 Abs #957: METHODS Abs #957: RESULTS The median follow-up time was 65 months The 5 year LRC and overall survival rates for all patients were 94.2% and 87.9%, respectively The 5-year LRC rate was significantly better in patients with carcinoma of Luminal A and B than Her-2 or basal phenotypes A significantly higher proportion of patients with Her-2 and basal subtypes had pathologic complete response, smaller pathologic tumor size, less than 4 LN with disease, and higher nuclear grade. 27
28 Abs #957: RESULTS In addition, on univariate analysis, CSIII, >4 LN +, LVI+ and high nuclear grade significantly stratified patients with lower 5 year LRC. Among pts with no pcr or > 4LN after NCT, those with Her2+ and basal subtypes had poor 5 yr LRC while those with LumA and B subtypes still had good LRC Abs #957: RESULTS 28
29 Abs #957: RESULTS Abs #957: RESULTS 29
30 Abs #957: RESULTS Abs #957: AUTHOR s CONCLUSIONS 30
31 ER+ PR+ Her2- ER- PR- Her2+ 31
32 Abs #4104: Targeted Intraoperative Radiotherapy (Targit) Boost after Breast Conserving Surgery Results in a Remarkably Low Recurrence Rate in a Standard Risk Population: 5 Year Results Jayant S Vaidya1, Michael Baum1, Jeffrey S Tobias1, Frederick Wenz2, Samuele Massarut3, Mohammed Keshtgar1, Basil Hilaris4, Christobel Saunders5, Norman R Williams1, Chris Brew-Graves1, Tammy Corica5,Mario Roncadin3, Uta Kraus- Tiefenbacher2, Max Bulsara5, David Joseph5 Abs #4104: METHODS Patients: Suitable for breast conserving surgery from UK, USA, Australia, Germany and Italy. All patients had breast conserving surgery + Targit boost + EBRT Treatment: Wide local excision + axillary surgery TARGeted Intraoperative radiotherapy (TARGIT) was delivered to the tumour bed immediately after surgical excision during the same anaesthesia as previously described. In some patients especially in the Australian cohort, due to logistic reasons, this procedure was performed as a second operation within a few weeks. All patients received external beam radiotherapy to the whole breast as per local protocol, delivering 50Gy in 25 fractions over 5 weeks. 32
33 Abs #4104: METHODS Targeted Intraoperative radiotherapy was delivered using the Intrabeam device. The size of the tumour bed determined the size of the applicator (2.5 cm to 5cm diameter) The radiation dose received by the tumour bed was between 18 to 20 Gy. The dose at 1cm was 5Gy, over minutes. The additional theatre time required for intraoperative radiotherapy was between 30 and 50 minutes, depending on the size of the applicator. Abs #4104: METHODS After completion of radiotherapy, the wound was closed and patients discharged home as usual. Patients were followed up as per local protocols, which all included at least a 6-12 monthly clinical examination and an annual mammogram. Statistical analysis for local recurrence was performed using SPSS software and compared with contemporary literature8,9. Cosmetic outcome was measured using standard techniques. 33
34 Abs #4104: METHODS Abs #4104: RESULTS 34
35 Abs #4104: RESULTS Abs #4104: RESULTS 35
36 Abs #4104: RESULTS Updates by the EBCTCG: Sarah Darby BCS +/- RT trials 11,000 women in 17 trials Median F/U 10 years Lumpectomy and L I- II ALND RT to conserved breast Boost in some Chemotherapy: few CMF/ no adriamycin Tamoxifen: most 36
37 Updates by the EBCTCG: Sarah Darby 15 year outcomes: Local Recurrence 5 YR 10 YR 15 YR NO RT 19.6% 26.2% 27.8% RT 5.3% 8.3% 9.9% Mortality 5 YR 10 YR 15 YR NO RT 7.8% 17.2% 25.3% RT 6.9% 14.6% 21.7% Pathologic Staging now 80% complete 15 year outcomes among NODE +, 1111 women: Local Recurrence 5 YR 10 YR 15 YR NO RT 40.5% 46.4% NA RT 11.2% 13.8% NA Mortality 5 YR 10 YR 15 YR NO RT 22.3% 41.9% 50.6% RT 20.4% 35.7% 44.0% 37
38 Pathologic Staging now 80% complete 15 year outcomes among NODE - : Local Recurrence 5 YR 10 YR 15 YR NO RT 17.5% 23.5% 24.9% RT 5.0% 7.6% 9.4% Mortality 5 YR 10 YR 15 YR NO RT 5.5% 12.8% 20.6% RT 4.6% 11.1% 17.4% 38
Current Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationdoi: /j.ijrobp
doi:10.1016/j.ijrobp.2009.12.047 Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 4, pp. 977 984, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ see front matter
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationAccelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation OSCO/OU Stephenson Cancer Center Saturday, March 5, 2016 Robert Kuske, MD, FAACE Founder, Medical Director Arizona Breast Cancer Specialists Scottsdale, Arizona 1
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationIntra operative Intrabeam radiation for breast cancer
Intra operative Intrabeam radiation for breast cancer Dr Gillian Campbell Radiation Oncologist May 2018 Disclaimer/Conflicts I am a radiation oncology consultant at Christchurch Hospital, Canterbury Breast
More informationTrends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States
Trends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationPartial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationAccelerated Partial Breast Irradiation (APBI)
Accelerated Partial Breast Irradiation (APBI) Michael Zhang (MSIV), Matthew Spraker, MD, PhD (PGY3) Faculty Mentor: Janice Kim, MD University of Washington/Seattle Cancer Care Alliance Seattle, WA Case
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationEvaluation of three APBI techniques under NSABP B-39 guidelines
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 11, NUMBER 1, WINTER 2010 Evaluation of three APBI techniques under NSABP B-39 guidelines Daniel Scanderbeg, a Catheryn Yashar, Greg White, Roger Rice,
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationAdvances in Breast Cancer
Advances in Breast Cancer Developed in collaboration Learning Objectives Upon completion, participants should be able to: Apply genomic medicine to treatment decisions for patients with HR+/HER2- early
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationAccelerated partial breast irradiation: state of the art
Accelerated partial breast irradiation: state of the art P.A. Coucke, N. Jansen, L. Jánváry, C. Louis, J. Vanderick, A. Rorive, J. Collignon, E. Lifrange, S. Maweja, G. Jerusalem Accelerated partial breast
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationBreast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationBrachytherapy: The precise answer for tackling breast cancer. Because life is for living
Brachytherapy: The precise answer for tackling breast cancer Because life is for living Table of contents Executive summary 3 Introduction 4 Management of early stage breast cancer 5 Radiotherapy options
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationEARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT
May 13, 2016 EARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. List treatment options for early stage breast cancer. 2.
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
doi:10.1016/j.ijrobp.2007.02.026 Int. J. Radiation Oncology Biol. Phys., Vol. 69, No. 1, pp. 32 40, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front matter
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationPavel ŠLAMPA, Jana RUZICKOVA, Barbora ONDROVA, Hana TICHA, Hana DOLEZELOVA
Sole conformal perioperative interstitial brachytherapy of early stage breast carcinoma using high-dose rate afterloading: longer-term results and toxicity Received: 0.09.2007 Accepted: 7.02.2008 Subject:
More informationWhat are Adequate Margins of Resection for Breast-Conserving Therapy?
What are Adequate Margins of Resection for Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School What are Adequate Margins
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationBruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationDuctal Carcinoma In Situ: Review of the Role of Radiation Therapy and Current Controversies
Ductal Carcinoma In Situ: Review of the Role of Radiation Therapy and Current Controversies Frank Vicini, MD, FACR, and Chirag Shah, MD Abstract Despite a lack of randomized trials comparing breast-conserving
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationUniversity of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationAccelerated Partial Breast Irradiation: Potential Roles Following Breast-Conserving Surgery
APBI is a promising technique in selected patients with early-stage breast cancer, but further study is needed on outcome and toxicity associated with this approach. Nick Patten. Passing Light (detail).
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2013 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationSlide 1. Slide 2. Slide 3 History of Nurse Navigator
Slide 1 The Nurse Navigators role in Early Stage Breast Cancer, and Development of Tailored Treatment Plan Laura Ochoa, RN, ANP-BC, Ph.D. Slide 2 Barnes Jewish Hospital at Washington University Slide 3
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationPatient Selection for APBI. C. Polgár National Institute ofoncology, Budapest, Hungary
Patient Selection for APBI C. Polgár National Institute ofoncology, Budapest, Hungary Patient-, tumour- and treatment related factors affecting decision making in patient selection for APBI Patient age
More informationDuctal Carcinoma in Situ (DCIS)
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Versions 2002 2017: Audretsch / Blohmer / Brunnert / Budach /
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2012 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationIndications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer
Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer Wendy A. Woodward, M.D. Ph.D. A sociate Profesor Section Chief, Breast Radiation Oncology
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 27 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationMultidisciplinary management of breast cancer
Multidisciplinary management of breast cancer C. Polgár 1,2 1 National Institute of Oncology 2 Semmelweis University Department of Oncology Incidence of breast cancer in Hungary 2014 Female population
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationState of the Art in 2000 State of the Art today Gazing forward
2010 Buschke Lecture: The Relationship between Local Recurrence and Survival in Breast Cancer Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School
More informationRecent Advances in Breast Radiotherapy
Recent Advances in Breast Radiotherapy Dr Anna Kirby Consultant Clinical Oncologist 2 The Royal Marsden Overview: Key innovations 1. 2D to 3D planning 2. Hypofractionation 3. Intensity modulated radiotherapy
More informationDisclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP120 Section: Medical Benefit Policy Subject: Intracavitary Balloon Brachytherapy for Breast Cancer I. Policy: Intracavitary Balloon Brachytherapy for Breast Cancer
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationBreast Health. Program Objectives. Facts About Breast Cancer in the United States
Breast Health Meridian Cancer Care Yolanda Tammaro, M.D. Meridian Medical Group- Specialty Care Breast Surgery, Ocean Medical Center Program Objectives Participants will: Learn some basic breast cancer
More informationClinical Investigation: Breast Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer How Do the ASTRO Consensus Statement Guidelines for the Application of Accelerated Partial
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationWelcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:
More information1. Screening, Diagnosis and Surgical Management of Breast Cancer
1. Screening, Diagnosis and Surgical Management of Breast Cancer Dr Melanie Walker, MBBS, FRACS (Breast Surgeon) Oncoplastic Breast Surgery Combination of optimal cancer surgery with plastic surgical techniques
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationBy Rufus Mark, MD, Gail Lebovic, MD, Valerie Gorman, MD, Oscar Calvo, PhD. TABLE 1 EARLY STAGE BREAST CANCER RANDOMIZED TRIALS M vs.
EVOLUTION OF BREAST CONSERVATION RADIATION TREATMENT TECHNIQUES IN BREAST CANCER : FROM 6 WEEKS TO 3 WEEKS TO 1 WEEK TO 1 DAY AND FROM WHOLE BREAST TO PARTIAL BREAST By Rufus Mark, MD, Gail Lebovic, MD,
More informationWhy Choose Brachytherapy and Not External Beam RT or IORT?
May 30 31, 2014 Miami Beach, FL USA Why Choose Brachytherapy and Not External Beam RT or IORT? Csaba Polgár, MD, PhD, MSc National Institute of Oncology Budapest, Hungary 1 Disclosure Csaba Polgár, MD,
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationClassifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology
2059 Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences Eugene Huang,
More informationSeptember 9, IORT Shows Promise in Early Use
An actual intraoperative delivery; a Xoft unit is attached to a balloon ready for treatment. September 9, 2011 IORT Shows Promise in Early Use A look at techniques and appropriate uses for this emerging
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationFirst results from the clinically controlled randomized DBCG PBI trial
First results from the clinically controlled randomized DBCG PBI trial BV Offersen 1, MS Thomsen 1, HM Nielsen 1, EH Jacobsen 2, M Berg 2, MH Nielsen 3, E Lorenzen 3, L Stenbygaard 4, I Jensen 4, AN Petersen
More informationAccelerated Partial Breast Irradiation: A Review and Description of an Early North American Surgical Experience With the Intrabeam Delivery System
A variety of techniques for accelerated partial breast irradiation are available. Photo courtesy of Lisa Scholder. Hidden Power, 24ʺ 28ʺ. Accelerated Partial Breast Irradiation: A Review and Description
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationAccelerated partial breast irradiation (APBI) has been in
ORIGINAL ARTICLE Six-Year Results From a Phase I/II Trial for Hypofractionated Accelerated Partial Breast Irradiation Using a 2-Day Dose Schedule John B. Wilkinson, MD,* Peter Y. Chen, MD,w Michelle F.
More information